Galil Medical

Company Overview

Snapshot

Founded in January 1997, Galil Medical operated with 1–10 employees and was acquired by BTG plc in May 2016. The company secured funding from 3 investors across one disclosed funding round.

Business overview

Galil Medical develops cryotherapy solutions for various patient conditions across multiple physician specialties, including kidneys, liver, lungs, prostate, bones, and targeted pain and nerve applications. Its core technology utilizes the Joule-Thomson effect, employing compressed argon gas to produce extremely low temperatures that ablate diseased tissue through freezing. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers globally.

Strategic signal

In May 2016, Galil Medical was acquired by BTG plc for $110 million. This acquisition highlights the strategic value of cryotherapy solutions in the medical technology landscape, signaling strong market interest in innovative, minimally-invasive cancer treatment methods. For investors, this demonstrates a successful exit for a company specializing in advanced medical devices, validating the potential for significant returns in this niche.

Company Intelligence Q&A

When was Galil Medical acquired and by whom?

Galil Medical was acquired by BTG plc in May 2016.

What is the core technology behind Galil Medical's products?

Galil Medical's core technology is based on the Joule-Thomson effect, which uses compressed argon gas to produce extremely low temperatures for cryoablation, effectively destroying diseased tissue through freezing.

Which investors participated in Galil Medical's funding round?

In December 2006, Galil Medical received funding from investors including.

What was the reported acquisition amount for Galil Medical?

BTG plc acquired Galil Medical for $110 million in May 2016.